Evidence map›Paper›PMID 38808779›Full record

ArticleAging cell2024

Unveiling ceramide dynamics: Shedding light on healthy aging in growth hormone-releasing hormone knockout mice.

Alexander Tate Lasher, Liping Wang, Jooyoung Hyun, Scott A Summers, Liou Y Sun

Abstract read
In one paragraph

Article in Aging cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. GHRH in diabetes and metabolism.Reviews in endocrine & metabolic disorders · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alexander Tate LasherDepartment of Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-6232-2844
Liping WangDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, USA.
Jooyoung HyunDepartment of Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Scott A SummersDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0002-4919-0592
Liou Y SunDepartment of Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-9802-6780

Funding

Ceramides as novel drivers of metabolic dysfunction and colorectal cancerU01CA272529 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Mary Christine Playdon, SCOTT A SUMMERS · 2022 to 2026
$4.7M
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesR44DK116450 · NIDDK · POTRERO HILL THERAPEUTICS, INC. · PI BLITZER, JEREMY, SUMMERS, SCOTT A · 2018 to 2022
$4.7M
The Role of Ceramides in Skeletal MuscleR01DK115824 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2018 to 2021
$2.6M
Longevity assurance interventions, metabolic health and Alzheimer's DiseaseR01AG057734 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SUN, LIOU · 2018 to 2022
$2.5M
The Role of Ceramides in the Pancreatic Beta CellR01DK130296 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HOLLAND, WILLIAM L, SUMMERS, SCOTT A · 2022 to 2025
$2.2M
Targeting a Ceramide Double Bond to Treat Cardiometabolic DisordersR01DK122001 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2019 to 2022
$1.9M
Targeting Ceramide Signaling: Enhancing Healthy Aging and Combating Tauopathy in MammalsR01AG085793 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SCOTT A SUMMERS, Liou Y. Sun · 2025 to 2026
$1.5M
Lifespan extension, Somatotropic signaling and TauopathyR21AG082327 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SUN, LIOU · 2023 to 2024
$408k
Longevity assurance interventions, metabolic health and Aβ toxicityR56AG057734 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SUN, LIOU · 2017 to 2017
$366k
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesR43DK116450 · NIDDK · POTRERO HILL THERAPEUTICS, INC. · PI BLITZER, JEREMY, SUMMERS, SCOTT A · 2017 to 2017
$225k
NCI NIH HHS U01 CA272529NIA NIH HHS R01 AG057734NIA NIH HHS R01 AG085793NIA NIH HHS R21 AG082327NIDDK NIH HHS R01 DK115824NIDDK NIH HHS R01 DK122001NIDDK NIH HHS R01 DK130296NIDDK NIH HHS R43 DK116450NIH HHS AG057734NIH HHS AG082327NIH HHS CA272529NIH HHS DK115824NIH HHS DK116450NIH HHS DK116888NIH HHS DK130296
6 · The paper itself

Abstract

Dysregulation of growth hormone (GH) signaling consistently leads to increased lifespan in laboratory rodents, yet the precise mechanisms driving this extension remain unclear. Understanding the molecular underpinnings of the beneficial effects associated with GH deficiency could unveil novel therapeutic targets for promoting healthy aging and longevity. In our pursuit of identifying metabolites implicated in aging, we conducted an unbiased lipidomic analysis of serum samples from growth hormone-releasing hormone knockout (GHRH-KO) female mice and their littermate controls. Employing a targeted lipidomic approach, we specifically investigated ceramide levels in GHRH-KO mice, a well-established model of enhanced longevity. While younger GHRH-KO mice did not exhibit notable differences in serum lipids, older counterparts demonstrated significant reductions in over one-third of the evaluated lipids. In employing the same analysis in liver tissue, GHRH-KO mice showed pronounced downregulation of numerous ceramides and hexosylceramides, which have been shown to elicit many of the tissue defects that accompany aging (e.g., insulin resistance, oxidative stress, and cell death). Additionally, gene expression analysis in the liver tissue of adult GHRH-KO mice identified substantial decreases in several ceramide synthesis genes, indicating that these alterations are, at least in part, attributed to GHRH-KO-induced transcriptional changes. These findings provide the first evidence of disrupted ceramide metabolism in a long-lived mammal. This study sheds light on the intricate connections between GH deficiency, ceramide levels, and the molecular mechanisms influencing lifespan extension.

Indexed as

AgingCeramidesGrowth Hormone-Releasing HormoneMice, KnockoutAnimalsFemaleLiverLongevityMiceCeramidesGrowth Hormone-Releasing HormoneagingceramideGHRHlifespanlipidomicslongevitymetabolic

Identifiers

PMID38808779
PMCPMC11320351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.